Ri Antibody Screen with Reflex to Titer and Western Blot

The Ri Antibody Screen with Reflex to Titer and Western Blot is a diagnostic panel offered by Quest Diagnostics, designed to detect the presence of Ri antibodies in the blood. Ri antibodies are autoantibodies, meaning they are produced by the body's immune system against its own tissues, specifically targeting neuronal (nerve cell) proteins. The presence of these antibodies is associated with a group of conditions known as paraneoplastic neurological syndromes (PNS), which are rare disorders that can affect various parts of the nervous system. These syndromes often develop in people who have cancer, as the immune system's response to the tumor mistakenly attacks neurons, leading to neurological symptoms. The initial part of the test, the Ri Antibody Screen, uses an immunofluorescence assay (IFA) technique to detect antibodies. If this screening test is positive, indicating the potential presence of Ri antibodies, the test reflexes, or automatically proceeds, to additional testing methods, such as a titer and possibly a Western Blot. The titer quantifies the amount of antibodies present, providing an indication of the immune response's intensity, while the Western Blot confirms the specificity of the antibodies for the Ri antigen. This panel is particularly important for diagnosing PNS early, which can then prompt further investigation for an underlying cancer, if not already known. It helps in the management of the neurological symptoms and the underlying cause, aiming to improve the patient's quality of life and outcome. A comprehensive approach, involving this panel, allows healthcare providers to make informed decisions regarding diagnosis, monitoring, and treatment strategies for affected individuals.